Die Zeit55 minutes agoBusiness1 min readGermanyView original

Fresenius completely takes over biopharma subsidiary mAbxience

Healthcare group strengthens business with copycat drugs by taking over the remaining 45 percent for up to 750 million euros.

fresenius mabxience biosimilars

Quick Look

The DAX group Fresenius is taking over the remaining 45 percent of its biopharma subsidiary mAbxience for up to 750 million euros.
The company in Bad Homburg is thus strengthening its business with biosimilars and further expanding the value chain.

AI-generated summary

Why It Matters

Fresenius acquired 55 percent of mAbxience in August 2022.

Font size

The healthcare group Fresenius is taking over its biopharma subsidiary mAbxience completely, thereby strengthening its business with copycat drugs. The DAX group will pay up to 750 million euros for the remaining 45 percent shares, as it announced in Bad Homburg. The sellers are the companies Insud and Invim. According to the information, the contract was signed and completed on Wednesday. Official approvals were not necessary.

Of the purchase price, 50 million euros are subject to one condition: Fresenius only has to pay it if certain production facilities have been approved. The group had already acquired a stake of 55 percent in mAbxience in August 2022.

Access to an attractive market

With the complete takeover, Fresenius is strengthening its access to the high-growth market for biosimilars, biotechnologically produced drugs for drugs whose patent has expired. Since health systems worldwide are under financial pressure, cheap imitation drugs play an important role in care.

Fresenius explained that protection for numerous biological drugs will expire in the future. “This high-growth market is expected to increase sixfold to more than 180 billion euros by 2035.”

Fresenius boss Michael Sen said: "With the completion of the acquisition of mAbxience, we are reaching the next milestone in building a leading, vertically integrated biopharma business of relevant size." The biosimilars platform is now completely bundled in Fresenius Kabi's biopharma business and covers the entire value chain from development to marketing.

When Fresenius first invested in mAbxience four years ago, the market potential was great and the biosimilars market was in an early phase, it said. Since then he has developed dynamically.